Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected zambian children: An observational study

Journal of Infectious Diseases

Volumn 196, Issue 3, 2007, Pages 347-355

  Moss, William J ^a   Scott, Susana ^e   Mugala, Nanthalile ^f   Ndhlovu, Zaza ^a   Beeler, Judy A ^d   Audet, Susette A ^d   Ngala, Mirriam ^f   Mwangala, Sheila ^f   Nkonga Mwangilwa, Chansa ^f   Ryon, Judith J ^a   Monze, Mwaka ^f   Kasolo, Francis ^f   Quinn, Thomas C ^b,c   Cousens, Simon ^e   Griffin, Diane E ^a   Cutts, Felicity T ^e  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f UNIVERSITY TEACHING HOSPITAL   (Zambia)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALE; MEASLES VACCINATION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVACCINATION; ZAMBIA;

ANTIBODIES, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; IMMUNIZATION, SECONDARY; INFANT; MALE; MEASLES; MEASLES VACCINE; ZAMBIA;

EID: 34447637606     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/519169     Document Type: Article

References (21)

1. Henao-Restrepo AM, Strebel P, Hoekstra EJ, Birmingham M, Bilous J. Experience in global measles control, 1990-2001. J Infect Dis 2003; 187(Suppl 1):S15-21.
2. Centers for Disease Control and Prevention. Progress in reducing global measles deaths, 1999-2004. MMWR Morb Mortal Wkly Rep 2006; 55:247-9.
3. Otten M, Kezaala R, Fall A, et al. Public-health impact of accelerated measles control in the WHO African Region 2000-03. Lancet 2005; 366:832-9.
4. Orenstein WA, Strebel PM, Papania M, Sutter RW, Bellini WJ, Cochi SL. Measles eradication: is it in our future? Am J Public Health 2000;90:1521-5.
5. Moss WJ, Cutts F, Griffin DE. Implications of the human immunodeficiency virus epidemic for control and eradication of measles. Clin Infect Dis 1999; 29:106-12.
6. Permar SR, Moss WJ, Ryon JJ, et al. Prolonged measles virus shedding in human immunodeficiency virus-infected children, detected by reverse transcriptase-polymerase chain reaction. J Infect Dis 2001; 183:532-8.
7. Scott S, Cumberland P, Shulman CE, et al. Neonatal measles immunity in rural Kenya: the influence of HIV and placental malaria infections on placental transfer of antibodies and levels of antibody in maternal and cord serum samples. J Infect Dis 2005; 191:1854-60.
8. Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 2003; 81:61-70.
9. Biellik R, Madema S, Taole A, et al. First 5 years of measles elimination in southern Africa: 1996-2000. Lancet 2002; 359:1564-8.
10. World Health Organization. Progress in measles control: Zambia, 1999-2004. Wkly Epidemiol Rec 2005; 80:213-7.
11. Albrecht P, Herrmann K, Burns GR. Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods 1981; 3:251-60.
12. Sato H, Albrecht P, Reynolds DW, Stagno S, Ennis FA. Transfer of measles, mumps, and rubella antibodies from mother to infant: its effect on measles, mumps, and rubella immunization. Am J Dis Child 1979; 133:1240-3.
13. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-42.
14. Sabin AB, Flores Arechiga A, Fernandez de Castro J, et al. Successful immunization of infants with and without maternal antibody by aerosolized measles vaccine. II. Vaccine comparisons and evidence for multiple antibody response. JAMA 1984; 251:2363-71.
15. Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. MMWR Morb Mortal Wkly Rep 1997; 46(RR-10):1-55.
16. National Center for Health Statistics. 2000 CDC growth charts. Clincial growth charts. Available at: http://www.cdc.gov/growthcharts. Accessed 20 August 2005.
17. Thaithumyanon P, Punnahitananda S, Thisyakorn U, Praisuwanna P, Ruxrungtham K. Immune responses to measles immunization and the impacts on HIV-infected children. Southeast Asian J Trop Med Public Health 2000; 31:658-62.
18. Oxtoby MJ, Ryder R, Mvula M, Nsa W, Baende E, Onorato I. Patterns of immunity to measles among African children infected with human immunodeficiency virus. In: Program and abstracts of Epidemic Intelligence Service Conference. Atlanta: Centers for Disease Control, 1989:31-2.
19. Arpadi SM, Markowitz LE, Baughman AL, et al. Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. Pediatrics 1996; 97:653-7.
20. Al-Attar I, Reisman J, Muehlmann M, McIntosh K. Decline of measles antibody titers after immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1995; 14:149-51.
21. World Health Organization. Strategies for reducing global measles mortality. Wkly Epidemiol Rec 2000; 75:411-6.